

CONTENTS

| | |
|--|-------|
| List of Tables in Text | xii |
| List of Tables in Appendices | xv |
| Preface | xvi |
| How to Use This Book | xviii |
| How to Use StudyWare™ to Accompany Pharmacological Aspects of Nursing Care, 7th Edition. | xxii |
| NCLEX-PN and NCLEX-RN Test Plans | xxx |

SECTION 1

Introduction to Drugs and Drug Administration

CHAPTER 1

Drugs/Agents and Factors Affecting

Their Action 2

| | |
|---|----|
| History | 3 |
| Sources of Drug | 4 |
| Drug Uses | 4 |
| Dosage Forms | 5 |
| Drug Names | 9 |
| Classification of Drugs. | 10 |
| Canadian Drug Legislation | 16 |
| Drug Information Resources | 16 |
| The Product Insert | 17 |
| Principles of Drug Action | 19 |
| Adverse Drug Effects | 20 |
| Pharmacokinetic Factors in Drug Therapy | 21 |
| Monitoring Drug Therapy | 25 |
| Individual Variation of Pharmacological Response | 26 |
| Drug Interactions. | 27 |
| Physical and Chemical Incompatibilities | 27 |
| Herbals and Botanical Medicine | 27 |

CHAPTER 2

Principles and Methods of Drug Administration 37

| | |
|---|----|
| The Nursing Process and Medication Administration | 37 |
| Administering Medications. | 39 |
| Nursing Process in Client Teaching | 63 |
| Fostering Compliance and Cooperation with Medication Regimens. | 66 |
| Nursing Process Approach to Improving Cooperation | 68 |

CHAPTER 3

Intravenous Drug Therapy 73

| | |
|--|----|
| Intravenous Infusion Therapy | 74 |
|--|----|

| | |
|--|----|
| Applying the Nursing Process | 79 |
| Electronic Infusion Devices. | 86 |

CHAPTER 4

Calculating Medication Dosages. 95

| | |
|--|-----|
| Interpreting the Drug Prescriptions | 95 |
| Ratio and Proportion. | 96 |
| Conversion between Systems of Measurement | 99 |
| Calculation of Fractional Doses | 102 |
| Calculation of Dosages Based on Weight | 103 |
| Pediatric Dosage Calculations. | 104 |
| Calculations Involving Intravenous Administration | 105 |
| Calculations Related to Solutions | 108 |
| Prevention of Medication Errors. | 109 |

CHAPTER 5

Drug Therapy for Pediatric Clients. 112

| | |
|--|-----|
| Pediatric Drug Therapy | 112 |
| Applying the Nursing Process | 116 |
| Nursing Children Receiving Medications | 116 |
| Poisoning | 125 |
| Herbals | 126 |

CHAPTER 6

Drug Therapy for Geriatric Clients 131

| | |
|---|-----|
| Geriatric Drug Therapy | 131 |
| Applying the Nursing Process | 134 |
| Nursing Care of Elderly Clients Receiving Drug Therapy | 134 |

SECTION 2

Agents That Interfere with Microbial Growth

CHAPTER 7

Antimicrobial Agents 144

| | |
|---|-----|
| Susceptibility of the Body to Infection. | 144 |
| Sources of Infection. | 146 |
| Identification of the Infecting Organism. | 148 |
| Selection of Antimicrobial Agents | 148 |
| Classification of Antimicrobial Agents. | 150 |
| Adverse Effects | 151 |
| Antibacterial Agents | 152 |
| Urinary Tract Anti-Infectives | 178 |
| Drugs Used to Treat Tuberculosis | 180 |
| Drugs Used to Treat Lyme Disease | 181 |
| Antifungal Drugs | 183 |
| Antiviral Drugs. | 186 |
| Miscellaneous Anti-Infective Agents. | 195 |

| | |
|---|-----|
| Leprostatic Agents | 195 |
| Applying the Nursing Process | 196 |
| Clients Receiving Penicillins | 199 |
| Clients Receiving Cephalosporins | 201 |
| Clients Receiving Tetracyclines | 201 |
| Clients Receiving Aminoglycosides | 202 |
| Clients Receiving Chemotherapy for Tuberculosis | 203 |
| Clients Receiving Sulfonamides and Urinary Tract Anti-Infectives | 204 |
| Clients Receiving Antifungal Agents | 206 |
| Clients Receiving Antiviral Agents | 207 |
| Clients with AIDS Receiving Drug Treatment | 208 |
| Nursing Care Plan: A Client with Urinary Tract Infection Taking Trimethoprim/ Sulfamethoxazole and Phenazopyridine HCl | 210 |
| Nursing Care Plan: A Client with Acquired Immunodeficiency Syndrome | 212 |

CHAPTER 8

Antiparasitic Drug Therapy 219

| | |
|--|-----|
| Protozoa | 219 |
| Systemic Parasitic Infections | 220 |
| Other Protozoal Infections | 221 |
| Anthelmintic Agents and Intestinal Parasitic Disorders | 225 |
| Dermatological Parasitic Disorders | 226 |
| Applying the Nursing Process | 228 |
| Clients Receiving Antimalarial Drugs | 228 |
| Clients Receiving Drugs for Amebiasis and Trichomonal Infections | 229 |
| Clients Receiving Anthelmintics | 230 |
| Clients Receiving Drugs for Dermatological Parasites | 231 |
| Nursing Care Plan: A Client with Pinworms Taking Thiabendazole (Mintezol) Suspension | 232 |

CHAPTER 9

Antiseptics and Disinfectants 239

| | |
|--|-----|
| Phenolic Agents | 240 |
| Alcohols | 245 |
| Aldehydes | 245 |
| Acids | 246 |
| Iodine and Iodophors | 246 |
| Chlorine and Chlorophors | 246 |
| Mercury Compounds | 247 |
| Silver Compounds | 247 |
| Surface-Active Agents | 247 |
| Oxidizing Agents | 247 |
| Chlorhexidine (Hibiclens, Hibistat, Exidine) | 247 |
| Applying the Nursing Process | 248 |
| Handwashing | 250 |

| | |
|--|-----|
| Nursing Care Plan: A Client with a Stage III Pressure Ulcer | 252 |
|--|-----|

SECTION 3: Agents Used to Control Pain and Inflammation

CHAPTER 10:

Analgesics and Antipyretics 258

| | |
|---|-----|
| Pain | 258 |
| Opioid Analgesics | 261 |
| Opioid Agonists | 269 |
| Opioid Antagonists | 270 |
| Nonopioid Analgesics | 270 |
| Analgesic Antipyretics | 271 |
| Applying the Nursing Process | 279 |
| Nonopioid Analgesics | 282 |
| Opioid Analgesics | 284 |
| Opioid Drugs and the Law | 285 |
| Client-Controlled Analgesia | 286 |
| Client-Controlled Oral Analgesia | 287 |
| Control of Chronic Pain | 288 |
| Pain Management in End-of-Life Care | 290 |

| | |
|---|-----|
| Nursing Care Plan: A Client Receiving Morphine Sulfate Following Appendectomy | 292 |
| Nursing Care Plan: A Client Receiving Morphine via Epidural Catheter Following Hysterectomy | 294 |

CHAPTER 11

Anesthetics 301

| | |
|---|-----|
| Anesthesia | 301 |
| Regional Anesthesia | 308 |
| Applying the Nursing Process | 314 |
| Clients with Malignant Hyperthermia | 316 |
| Nursing Care Following General Anesthesia | 317 |
| Safety and Anesthetic Agents | 318 |
| Nursing Care Following Regional (Local) Anesthesia | 318 |
| Overall Assessment | 319 |
| Nursing Care Plan: A Postsurgical Client | 320 |

CHAPTER 12

Anti-Inflammatory Agents 325

| | |
|--|-----|
| Nonsteroidal Anti-Inflammatory Drugs | 326 |
| Disease-Modifying Antirheumatic Drugs | 330 |
| Slow-Acting Antirheumatic Agents | 332 |
| Corticosteroids | 333 |
| Applying the Nursing Process | 340 |
| Clients Receiving Nonsteroidal Anti-Inflammatory Agents | 340 |

| | |
|--|------------|
| Clients Receiving Drug-Modifying Antirheumatic Drugs | 342 |
| Clients Receiving Slow-Acting Antirheumatic Drugs | 343 |
| Clients Receiving Corticosteroids | 344 |
| Nursing Care Plan: A Client with Arthritis Taking Adalimumab and Prednisone | 346 |

CHAPTER 13

Agents Used to Treat Hyperuricemia and Gout 352

| | |
|---|------------|
| Management of Acute Gouty Arthritis | 353 |
| Control of Hyperuricemia | 355 |
| Applying the Nursing Process | 356 |
| Nursing Care Plan: A Client with Hyperuricemia and Gout Taking Probenecid and Colchicine | 358 |

SECTION 4

Agents Used to Treat Respiratory Disorders

CHAPTER 14

Antihistamines and Nasal

| | |
|---|------------|
| Decongestants. | 364 |
| Antihistamines | 365 |
| Decongestants | 366 |
| Applying the Nursing Process | 373 |
| Nursing Care Plan: A Client with a Cold Taking Pseudoephedrine Hydrochloride (Sudafed) | 376 |

CHAPTER 15

Expectorant and Antitussive Agents . . 382

| | |
|--|------------|
| Expectorants | 382 |
| Antitussives | 383 |
| Applying the Nursing Process | 383 |
| Nursing Care Plan: A Child with Bronchitis Taking Guaifenesin (Robitussin) Syrup. | 388 |

CHAPTER 16

Bronchodilators and Other Respiratory Agents 393

| | |
|---|------------|
| Bronchodilators | 393 |
| Mucolytics | 400 |
| Mast Cell Stabilizers | 400 |
| Applying the Nursing Process | 402 |
| Nursing Care Plan: A Client with Asthma Using Cromolyn Sodium (Intal) and Terbutaline Sulfate (Brethine) | 406 |

SECTION 5

Agents Used to Treat Cardiovascular Disorders

CHAPTER 17

Cardiac Stimulants and Depressants . . 414

| | |
|---|------------|
| Cardiac Glycosides | 416 |
| Inamrinone Lactate (Inamrinone) and Milrinone Lactate (Primacor) | 419 |
| Antiarrhythmic/Antidysrhythmic Agents | 419 |
| Cardiac Stimulants Used to Treat Shock | 428 |
| Applying the Nursing Process | 431 |
| Clients Receiving Cardiac Glycosides | 431 |
| Clients Receiving Antidysrhythmic Agents | 434 |
| Clients in Cardiac Emergencies and Shock | 435 |
| Nursing Care Plan: An Insulin-Dependent Client with Cardiac Antidysrhythmia Taking Amiodarone Hydrochloride (Cordarone). | 436 |

CHAPTER 18

Agents That Dilate Blood Vessels 442

| | |
|---|------------|
| Coronary Vasodilators | 442 |
| Myocardial Infarction | 447 |
| Peripheral Vasodilators | 450 |
| Applying the Nursing Process | 450 |
| Clients Receiving Coronary Vasodilators | 450 |
| Clients Receiving Peripheral Vasodilators | 454 |
| Nursing Care Plan: A Client with Angina Using Transdermal Nitroglycerin (Nitro-Dur). | 455 |

CHAPTER 19

Agents Affecting Blood Clotting 461

| | |
|---|------------|
| Anticoagulants | 461 |
| Antiplatelet Agents | 467 |
| Thrombolytic Agents | 468 |
| Tissue Plasminogen Activator | 469 |
| Hemorheologic Agents | 469 |
| Hemostatic Agents | 469 |
| Applying the Nursing Process | 470 |
| Clients Receiving Anticoagulants | 470 |
| Comfort and Safety | 472 |
| Client Education | 474 |
| Nursing Care Following Intracoronary Thrombolysis | 475 |
| Nursing Care Plan: A Client with Acute Myocardial Infarction Receiving Alteplase (Activase), A Tissue Plasminogen Activator. | 477 |

CHAPTER 20

Diuretics and Antihypertensives. 482

| | |
|---------------------|-----|
| Diuretics | 482 |
|---------------------|-----|

| | |
|--|-----|
| Antihypertensive Agents | 488 |
| Applying the Nursing Process | 501 |
| Meeting Sodium and Potassium Needs | 502 |
| Limiting Adverse Effects | 503 |
| Long-Term Client Management | 505 |
| Management of Hypertensive Emergencies | 507 |
| Nursing Care Plan: A Client with Hypertension | |
| Taking Enalapril Maleate (Vasotec), | |
| Hydrochlorothiazide | 508 |

CHAPTER 21

Agents Used in the Treatment of Hyperlipidemia 514

| | |
|---|-----|
| Hyperlipidemia | 514 |
| Applying the Nursing Process | 519 |
| Nursing Care Plan: A Client with Hyperlipidemia Receiving Simvastatin (Zocor) | 520 |

CHAPTER 22

Agents Used to Treat Anemias 526

| | |
|---|-----|
| Iron Deficiency Anemia | 527 |
| Megaloblastic Anemias | 529 |
| Applying the Nursing Process | 532 |
| Nursing Care Plan: A Client with Crohn's Disease Taking Vitamin B ₁₂ | 534 |

CHAPTER 23

Vitamins, Minerals, and Other Nutritional Agents 539

| | |
|--|-----|
| Protein | 540 |
| Fat | 543 |
| Carbohydrate | 544 |
| Vitamins | 544 |
| Minerals | 547 |
| Total Parenteral Nutrition | 552 |
| Applying the Nursing Process | 553 |
| Nursing Care Plan: A Client with Congestive Heart Failure Receiving a Diuretic with a Potassium Supplement | 556 |

SECTION 6

Agents Used to Treat Gastrointestinal Disorders

CHAPTER 24

Agents Used to Treat Hyperacidity and Gastroesophageal Reflux Disease 564

| | |
|---|-----|
| Antacids | 565 |
| Histamine H ₂ Receptor Antagonists | 569 |
| Proton Pump Inhibitors | 570 |
| Sucralfate (Carafate) | 571 |
| Misoprostol (Cytotec) | 571 |

| | |
|---|-----|
| Metoclopramide (Reglan, Emex) | 571 |
| Gastrointestinal Enzymes | 572 |
| Applying the Nursing Process | 572 |
| Nursing Clients Taking Antacids | 572 |
| Nursing Clients Receiving Histamine H ₂ Receptor Antagonists, Proton Pump Inhibitors, and Sucralfate | 575 |
| Nursing Clients Taking Metoclopramide | 576 |
| Nursing Care Plan: A Client with Peptic Ulcer Disease Taking Antacids | 578 |
| Nursing Care Plan: A Client with Hiatal Hernia Taking Metoclopramide (Reglan) and Esomeprazole Magnesium (Nexium) | 580 |

CHAPTER 25

Emetics and Antiemetics 585

| | |
|--|-----|
| Emetics | 585 |
| Antiemetics | 586 |
| Applying the Nursing Process | 590 |
| Clients Taking Emetics | 590 |
| Clients Taking Antiemetics | 591 |

CHAPTER 26

Laxatives and Antidiarrheals 596

| | |
|--|-----|
| Laxatives | 596 |
| Antidiarrheal Agents | 602 |
| Applying the Nursing Process | 604 |
| Clients Receiving Laxatives | 604 |
| Clients Receiving Antidiarrheal Agents | 607 |

SECTION 7

Agents Affecting the Nervous System

CHAPTER 27

Central Nervous System Sedatives and Hypnotics 614

| | |
|---|-----|
| Barbiturates | 614 |
| Benzodiazepines | 617 |
| Nonbenzodiazepines | 619 |
| Alcohol (Ethanol) | 620 |
| Other Sedative-Hypnotics | 620 |
| Applying the Nursing Process | 622 |
| Clients Receiving Sedative-Hypnotics | 622 |
| Clients Receiving Barbiturates | 623 |
| Clients Receiving Nonbarbiturates | 624 |
| Nursing Care Plan: A Client with Anxiety Taking Diazepam (Valium) | 627 |

CHAPTER 28

Anxiolytics and Other Agents Used to Treat Psychiatric Conditions 632

| | |
|--|-----|
| Antianxiety Agents (Anxiolytics) | 632 |
|--|-----|

| | |
|--|-----|
| Agents Used to Treat Affective Disorders | 638 |
| Antidepressant Agents | 638 |
| Antipsychotic Agents | 643 |
| Antimanic Agents | 645 |
| Applying the Nursing Process | 648 |
| Clients Receiving Drug Therapy for Anxiety and/or Psychiatric Conditions | 648 |
| Clients Receiving Anxiolytics | 650 |
| Clients Receiving Antidepressants | 651 |
| Clients Receiving Antipsychotic Agents | 653 |
| Clients Receiving Antimanic Agents | 657 |
| Nursing Care Plan: A Client with Bipolar Illness Taking Lithium Carbonate | 658 |

CHAPTER 29

| | |
|--|------------|
| Agents Used to Treat Attention-Deficit Hyperactivity Disorder and Alzheimer's Disease | 665 |
| Anorexiant | 666 |
| Atomoxetine Hydrochloride (Strattera) | 666 |
| Analeptics | 668 |
| Agents Used to Treat Alzheimer's Disease | 668 |
| Applying the Nursing Process | 671 |
| Clients Receiving Central Nervous System Stimulants | 671 |
| Clients Receiving Medications to Treat Alzheimer's Disease | 673 |
| Nursing Care Plan: A Child with Attention- Deficit Hyperactivity Disorder Taking Atomoxetine Hydrochloride (Strattera) | 674 |

CHAPTER 30

| | |
|--|------------|
| Agents Used in Musculoskeletal Disorders | 679 |
| Neuromuscular Blocking Agents | 680 |
| Centrally Acting Skeletal Muscle Relaxants | 682 |
| Direct-Acting Skeletal Muscle Relaxants | 685 |
| Skeletal Muscle Stimulants | 685 |
| Applying the Nursing Process | 688 |
| Clients Taking Neuromuscular Blocking Agents | 688 |
| Clients Taking Centrally Acting Skeletal Muscle Relaxants | 689 |
| Clients Taking Direct-Acting Skeletal Muscle Relaxants | 690 |
| Clients Taking Skeletal Muscle Stimulants | 691 |
| Nursing Care Plan: A Client with Myasthenia Gravis Taking Pyridostigmine Bromide (Mestinon) and Receiving Edrophonium Chloride (Tensilon, Reversol) | 692 |

CHAPTER 31

| | |
|--|------------|
| Anti-Parkinson Agents | 697 |
| Dopaminergic Agents | 698 |
| Anticholinergic Agents | 700 |

| | |
|--|-----|
| Catechol-O-Methyltransferase Inhibitors | 704 |
| Applying the Nursing Process | 704 |
| Nursing Care Plan: A Client with Parkinson's Disease Taking Carbidopa-Levodopa (Sinemet) | 706 |

CHAPTER 32

| | |
|--|------------|
| Anticonvulsants | 712 |
| Applying the Nursing Process | 731 |
| Nursing Care Plan: A Child with Epilepsy Taking Phenytoin (Dilantin) and Phenobarbital | 738 |

CHAPTER 33

| | |
|--|------------|
| Substance Abuse | 743 |
| Opiate Abuse | 745 |
| Central Nervous System Depressant Abuse | 748 |
| Central Nervous System Stimulants | 752 |
| Cannabis Abuse | 753 |
| Psychedelic Agents | 754 |
| "Ecstasy" | 755 |
| Tobacco | 755 |
| Inhalant Abuse | 757 |
| Applying the Nursing Process | 760 |
| Screening for Substance Abuse | 760 |
| Nursing Care for Substance Abuse | 761 |
| Nursing Care during Detoxification | 762 |
| Treatment of Substance Abuse | 763 |
| Impaired Health Care Workers | 763 |
| Establishing a Drug-Free Workplace | 764 |
| Substance Abuse Education | 764 |
| Nursing Care Plan: A Client with Substance Abuse Receiving Naloxone Hydrochloride (Narcan) | 766 |

CHAPTER 34

| | |
|---|------------|
| Autonomic Nervous System | 770 |
| The Sympathetic Nervous System | 771 |
| The Parasympathetic (Cholinergic) Nervous System | 773 |
| Agents That Affect the Autonomic Nervous System | 774 |
| Sympathomimetics (Adrenergics) | 774 |
| Sympatholytics (Adrenergic Blockers) | 775 |
| Parasympathomimetics (Cholinergics) | 776 |
| Parasympatholytics (Anticholinergics) | 776 |
| Antispasmodics | 779 |
| Applying the Nursing Process | 781 |
| Nursing Care Plan: A Client with an Overactive Bladder Taking Trosipium Chloride (Sanctura) | 783 |

SECTION 8 Agents Used to Correct Endocrine Imbalance

CHAPTER 35

Agents Affecting Thyroid, Parathyroid, and Pituitary Function 788

| | |
|---|-----|
| Thyroid Disorders | 789 |
| Parathyroid Disorders | 794 |
| Pituitary Disorders | 796 |
| Applying the Nursing Process | 798 |
| Clients Taking Thyroid Medication | 798 |
| Clients Taking Antithyroid Medication | 801 |
| Clients Taking Medication for Parathyroid Disorders | 803 |
| Clients Taking Pituitary Hormones | 805 |
| Nursing Care Plan: A Client with Diabetes Insipidus Using DDAVP Spray | 806 |

CHAPTER 36

Agents Used to Treat Hyperglycemia and Hypoglycemia. 813

| | |
|---|-----|
| Insulin Therapy | 815 |
| Islet Transplantation | 819 |
| Oral Hypoglycemic Agents | 819 |
| Parenteral Therapy for Type 2 Diabetes | 826 |
| Applying the Nursing Process | 827 |
| Decreasing Deficient Knowledge | 827 |
| Administration of Insulin by Pump | 830 |
| Storage and Care of Insulin and Supplies | 833 |
| Glucose Monitoring | 833 |
| Insulin Reactions and Diabetic Ketoacidosis | 834 |
| Safety Precautions | 836 |
| Nursing Care for Type 2 Diabetic Clients | 837 |
| Nursing Care Plan: A Client with Diabetes Using an Oral Hypoglycemic, Glipizide (Glucotrol) | 838 |

SECTION 9 Agents Affecting the Reproductive System

CHAPTER 37

Sex Hormones 846

| | |
|--|-----|
| Female Sex Hormones | 847 |
| Estrogen and Progesterone Combinations | 854 |
| Ovulation Stimulants | 854 |
| Male Sex Hormones | 858 |
| Impotence | 859 |
| Anabolic Agents | 861 |

| | |
|---|-----|
| Danazol (Cyclomen, Danocrine) | 862 |
| Nafarelin Acetate (Synarel) and Histrelin Acetate (Vantus) | 863 |
| Leuprolide Acetate (Lupron Depot) | 863 |
| Androgen Hormone Inhibitors | 863 |
| Tamsulosin Hydrochloride (Flomax) | 864 |
| Applying the Nursing Process | 864 |
| Clients Taking Ovulation Stimulants | 867 |
| Nursing Care Plan: A Client with Endometriosis Treated with Leuprolide Acetate (Lupron Depot) | 868 |
| Clients Receiving Agents to Treat Erectile Dysfunction | 870 |

CHAPTER 38

Agents Used in Obstetrical Care 874

| | |
|---|-----|
| Uterine Stimulants | 874 |
| Abortifacients | 876 |
| Uterine Relaxants | 877 |
| Lactation Suppressants | 877 |
| Rh ₀ (D) Immune Globulin (BayRho-D, RhoGAM, MICRhoGAM, WinRho) | 878 |
| Applying the Nursing Process | 878 |
| Clients Taking Drugs That Influence Labor and Delivery | 878 |
| Clients Taking Abortifacients | 879 |
| Clients Taking Uterine Relaxants | 881 |
| Clients Taking Lactation Suppressants or Stimulants | 883 |
| Nursing Care Plan: A Pregnant Client Using Ritodrine Hydrochloride | 884 |

SECTION 10 Agents Affecting Immunity

CHAPTER 39

Agents That Affect Immunity 892

| | |
|--|-----|
| Agents That Provide Active or Passive Immunity | 893 |
| Interferons and Interleukins | 893 |
| Immunosuppressant Agents | 910 |
| Antiviral Agents for Human Immunodeficiency Virus | 914 |
| Drugs Used to Treat Gaucher's Disease | 914 |
| Applying the Nursing Process | 915 |
| Clients Receiving Agents to Enhance the Immune System | 915 |
| Clients Receiving Agents to Suppress the Immune System | 917 |
| Nursing Care Plan: A Client Receiving Muromonab-CD3 (Orthoclone OKT 3) Following Heart Transplantation | 918 |

CHAPTER 40**Agents Used in the Treatment of Cancer 925**

| | |
|---|-----|
| Alkylating Agents | 928 |
| Antimetabolites | 928 |
| Mitotic Inhibitors | 928 |
| Antibiotics | 929 |
| Hormones | 930 |
| Corticosteroids | 930 |
| Radioactive Drugs | 930 |
| Biological-Response Modifiers | 930 |
| Miscellaneous Antineoplastic Agents | 930 |
| Monoclonal Antibodies | 930 |
| Protease Inhibitors | 930 |
| Combination Therapy | 931 |
| Adjuvant Agents | 931 |
| Antiemetics | 934 |
| Applying the Nursing Process | 934 |
| Special Drug Delivery Methods | 958 |
| Safe Handling of Cytotoxic Agents | 963 |
| Nursing Care Plan: A Client Receiving Chemotherapy for Lung Cancer | 964 |
| Clients Receiving Investigational Agents | 967 |

SECTION 11**Agents Used to Treat Eye, Ear,
and Skin Disorders****CHAPTER 41****Agents Used in the Treatment of Eye Disorders 974**

| | |
|--|-----|
| Mydriatic Agents | 974 |
| Ophthalmic Anti-Infectives | 975 |
| Antiseptics | 979 |
| Local Anesthetics | 979 |
| Corticosteroids | 979 |
| Nonsteroidal Anti-Inflammatory Agents | 980 |
| Miscellaneous Agents | 981 |
| Glaucoma | 981 |
| Agents That Decrease the Formation of Aqueous Humor | 982 |
| Agents That Increase the Outflow of Aqueous Humor | 984 |
| Agents That Decrease Formation and Increase Outflow of Aqueous Humor | 986 |
| Applying the Nursing Process | 988 |
| Clients with Glaucoma | 990 |
| Nursing Care Plan: A Client with an Eye Infection Using Vidarabine Ointment (Vira-A) | 994 |

| | |
|--|-----|
| Nursing Care Plan: A Client with Glaucoma Using Pilocarpine via Ocusert Therapeutic System | 996 |
|--|-----|

CHAPTER 42**Agents Used in the Treatment of Ear Disorders 1001**

| | |
|---|------|
| Drugs Used in Otic Therapy | 1002 |
| Antimicrobials | 1002 |
| Applying the Nursing Process | 1004 |
| Nursing Care Plan: A Client with Otitis Media Receiving Amoxicillin/Potassium Clavulanate (Augmentin) | 1006 |

CHAPTER 43**Agents Used in the Treatment of Skin Disorders 1010**

| | |
|---|------|
| Drugs Used in Dermatological Therapy | 1012 |
| Diabetic Foot Ulcers | 1020 |
| Antineoplastic Agents | 1020 |
| Agents Used to Treat Eczema | 1021 |
| Agents Used to Treat Psoriasis | 1022 |
| Agents Used to Treat Burns | 1022 |
| Minoxidil (Rogaine) | 1022 |
| Masoprocol (Actinex) | 1022 |
| Applying the Nursing Process | 1024 |
| Clients Receiving Antifungal Agents | 1025 |
| Nursing the Burn Client | 1027 |
| Nursing Care Plan: A Child with Burns Being Treated with Silver Sulfadiazine | 1028 |

| | |
|--|------|
| Appendix 1: Nomograms for Children and Adults | 1034 |
| Appendix 2: Diagnostic Agents | 1036 |
| Appendix 3: Approximate Normal Values | 1040 |
| Appendix 4: Toxicology Overview | 1043 |
| Appendix 5: Common Food/Drug/Herbal Interactions | 1047 |
| Appendix 6: Spanish and French Translations of Common Medication Instructions | 1062 |
| Appendix 7: Abbreviations Commonly Found in Drug Prescriptions | 1065 |

| | |
|----------------------|------|
| Glossary | 1067 |
| References | 1087 |
| Index | 1089 |

LIST OF TABLES

| | | |
|------------------|--|-----|
| TABLE 1-1 | Herbs | 30 |
| 2-1 | Abbreviations Commonly Found in Drug Prescriptions | 42 |
| 2-2 | Potentially Confusing Abbreviations, Acronyms, and Symbols: A List from the Joint Commission on Accreditation of Healthcare Organizations | 43 |
| 2-3 | Some Commonly Used Approximate Weight and Measure Equivalents | 45 |
| 2-4 | Types of Syringes in Common Use. | 47 |
| 2-5 | Common Routes of Drug Administration | 49 |
| 2-6 | Administration of Oral Medications | 53 |
| 2-7 | Selection of Needles for Injection | 55 |
| 3-1 | Common Intravenous Solutions | 75 |
| 4-1 | Amount/Dosage | 96 |
| 4-2 | Preparations | 96 |
| 4-3 | Routes | 97 |
| 4-4 | Special Instructions. | 97 |
| 4-5 | Times. | 97 |
| 4-6 | Values of Single Roman Numbers | 98 |
| 4-7 | Metric Prefixes | 99 |
| 4-8 | Common Metric Abbreviations | 100 |
| 4-9 | Liquid Measure in the Apothecary System. | 101 |
| 4-10 | Apothecary Notation | 101 |
| 5-1 | Classification of Pediatric Clients. | 113 |
| 5-2 | Guidelines for the Administration of Oral and Parenteral Medications to Young Children. | 118 |
| 7-1 | Penicillins | 155 |
| 7-2 | Cephalosporins. | 161 |
| 7-3 | Tetracyclines | 166 |
| 7-4 | Macrolides/Erythromycins | 167 |
| 7-5 | Aminoglycosides. | 169 |
| 7-6 | Fluoroquinolones | 170 |
| 7-7 | Other Antibacterial Agents. | 173 |
| 7-8 | Sulfonamide Products for Systemic Use. | 179 |
| 7-9 | Laboratory Test Interactions. | 181 |
| 7-10 | Antitubercular Drugs | 182 |
| 7-11 | Antiviral Drugs | 187 |
| 7-12 | Antiviral Drug Interactions | 195 |
| 8-1 | Drugs Used in the Treatment of Malaria | 222 |
| 8-2 | Drugs of Choice for the Treatment of Intestinal Parasitic Worm Infestations | 226 |
| 9-1 | Commonly Used Antiseptics and Disinfectants | 241 |
| 10-1 | Receptor Activity Related to Some Analgesic Drugs. | 261 |
| 10-2 | Opioid Analgesics | 263 |
| 10-3 | Equianalgesic Doses of Opioid Analgesics | 268 |
| 10-4 | Opioid Antagonists. | 271 |
| 10-5 | Nonopioid Analgesics. | 272 |
| 10-6 | Some Popular Opioid Analgesic Combination Products | 275 |
| 10-7 | Drug Products Used to Treat Migraine Headaches. | 276 |
| 10-8 | Drug Products Used for Client-Controlled Analgesia | 289 |
| 11-1 | Changes in Body Function during Stages and Planes of Anesthesia. | 303 |
| 11-2 | General Anesthetics Administered by Inhalation | 305 |
| 11-3 | General Anesthetics Administered by Injection | 307 |

| | | |
|-------------------|--|-----|
| TABLE 11-4 | Drugs Used as Adjuncts to General Anesthesia | 309 |
| 11-5 | Common Types of Regional Anesthesia | 311 |
| 11-6 | Regional Anesthesia Agents | 312 |
| 12-1 | Nonsteroidal Anti-Inflammatory Agents | 327 |
| 12-2 | Disease-Modifying Antirheumatic Drugs | 331 |
| 12-3 | Slow-Acting Antirheumatic Agents | 333 |
| 12-4 | Corticosteroids for Systemic Use | 335 |
| 12-5 | Corticosteroids Administered by Local Injection | 337 |
| 12-6 | Corticosteroids for Topical Use | 337 |
| 13-1 | Drugs Used to Treat Gout | 354 |
| 14-1 | Antihistamines | 368 |
| 14-2 | Decongestants | 370 |
| 14-3 | Intranasal Steroid Products | 372 |
| 15-1 | Expectorants | 384 |
| 15-2 | Antitussives | 385 |
| 16-1 | Sympathomimetic Bronchodilators | 395 |
| 16-2 | Xanthine Bronchodilators | 399 |
| 16-3 | Corticosteroids Used by Inhalation in the Treatment of Bronchial Asthma | 402 |
| 17-1 | Cardiac Glycosides in Current Use | 417 |
| 17-2 | Antiarrhythmic Drugs | 420 |
| 17-3 | Antiarrhythmic/Antidysrhythmic Drugs in Current Use | 425 |
| 17-4 | Agents Used in the Treatment of Shock | 430 |
| 18-1 | Nitrates Used in the Treatment of Angina | 445 |
| 18-2 | Non-Nitrates Used in the Treatment of Angina Pectoris | 447 |
| 19-1 | Blood Clotting Factors | 462 |
| 19-2 | Dosage Guidelines for Administering Heparin | 464 |
| 19-3 | Oral Anticoagulants | 465 |
| 20-1 | Thiazide Diuretics | 484 |
| 20-2 | Nonthiazide Diuretics | 486 |
| 20-3 | Nondiuretic Antihypertensive Agents | 494 |
| 21-1 | Classes of Lipoproteins | 515 |
| 21-2 | Effects of Antihyperlipidemic Drugs on Serum Lipids and Lipoproteins | 518 |
| 22-1 | Iron Preparations | 529 |
| 23-1 | Comparison of Selected Nutrients in the Dietary Approaches to Stop Hypertension (DASH) Eating Plan, the USDA Food Guide, and Nutrient Intakes Recommended per Day by the Institute of Medicine (IOM) | 542 |
| 23-2 | Some Potassium-Rich Foods | 549 |
| 24-1 | Active Ingredients in Antacid Products | 567 |
| 24-2 | Histamine H ₂ Receptor Antagonists | 569 |
| 25-1 | Antiemetics | 587 |
| 26-1 | Stimulant Laxatives | 597 |
| 26-2 | Saline Laxatives | 598 |
| 26-3 | Bulk-Forming Laxatives | 600 |
| 26-4 | Stool Softeners | 601 |
| 26-5 | Antidiarrheal Drugs That Reduce Gastrointestinal Motility | 603 |
| 27-1 | Barbiturates Used as Sedatives and Hypnotics | 615 |
| 27-2 | Benzodiazepines Used as Hypnotic Agents | 617 |
| 27-3 | Nonbarbiturates/Sedative-Hypnotic Agents | 620 |
| 28-1 | Oral Anxiolytic Agents | 635 |
| 28-2 | Monoamine Oxidase Inhibitors | 639 |
| 28-3 | Some Tyramine-Rich Foods | 640 |
| 28-4 | Antidepressants | 641 |

| | | |
|-------------------|--|-----|
| TABLE 28-5 | Antipsychotic Drugs | 646 |
| 29-1 | Anorectic Agents. | 666 |
| 29-2 | Nonanorectic Central Nervous System Stimulants | 668 |
| 29-3 | Caffeine Content of Common Beverages. | 669 |
| 30-1 | Neuromuscular Blocking Agents (Intravenous) | 681 |
| 30-2 | Centrally Acting Skeletal Muscle Relaxants | 683 |
| 30-3 | Anticholinesterase Muscle Stimulants | 687 |
| 31-1 | Drugs Used to Treat Parkinson's Disease | 701 |
| 32-1 | Anticonvulsants in Current Use | 718 |
| 32-2 | Drug Interactions with Common Anticonvulsants | 728 |
| 33-1 | Effects of Various Blood Alcohol Concentrations on the Human Body | 750 |
| 33-2 | Common Drugs and Symptoms of Abuse | 757 |
| 34-1 | Some Organ Responses to Autonomic Nerve Impulses | 773 |
| 34-2 | Anticholinergics That Are Belladonna Derivatives | 777 |
| 34-3 | Synthetic Anticholinergics Used as Antispasmodics | 780 |
| 35-1 | Classification of Hyperthyroidism | 790 |
| 35-2 | Drugs Used to Treat Hyperthyroidism | 791 |
| 35-3 | Classification of Hypothyroidism | 793 |
| 35-4 | Thyroid Preparations | 795 |
| 35-5 | Drugs Used in the Treatment of Diabetes Insipidus. | 799 |
| 36-1 | Insulin Preparations | 818 |
| 36-2 | Administration of Insulins | 819 |
| 36-3 | Insulins Commonly Used in the United States | 820 |
| 36-4 | Less Commonly Used Insulins | 821 |
| 36-5 | Human and Analog Insulin: Time of Action | 821 |
| 36-6 | Insulin Capabilities/Nursing Implications. | 822 |
| 36-7 | Stability of In-Use Insulin at Room Temperature. | 823 |
| 36-8 | Oral Hypoglycemic Agents. | 824 |
| 36-9 | Conversion of the A-1-C to Average Blood Sugar | 826 |
| 37-1 | Estrogen Products | 849 |
| 37-2 | Progestational Products | 852 |
| 37-3 | Oral Contraceptive Products | 855 |
| 37-4 | Topical Contraceptives | 859 |
| 37-5 | Androgen Products | 861 |
| 37-6 | Anabolic Products. | 862 |
| 39-1 | Agents Used in Providing Passive Immunity | 894 |
| 39-2 | Agents Used for Active Immunization | 898 |
| 39-3 | Recommended Childhood Immunization Schedule | 908 |
| 39-4 | Agents Used in the Prophylaxis of Rabies | 910 |
| 40-1 | Neoplastic Disorders in Which Chemotherapy Has Significantly Prolonged Survival | 927 |
| 40-2 | Antineoplastic Agents' Potential for Causing Nausea/Vomiting. | 931 |
| 40-3 | Examples of Combination Chemotherapeutic Regimens | 932 |
| 40-4 | Commonly Used Anticancer Drugs | 935 |
| 41-1 | Sympathomimetic Mydriatic Drugs | 976 |
| 41-2 | Anticholinergic Mydriatic Drugs | 977 |
| 41-3 | Antimicrobials Used to Treat Eye Infections | 978 |
| 41-4 | Local Anesthetics Used in the Eye | 980 |
| 41-5 | Carbonic Anhydrase Inhibitors Used in Glaucoma. | 983 |
| 41-6 | Osmotic Diuretics Used in Glaucoma | 985 |
| 41-7 | Direct-Acting Miotics Used in Glaucoma. | 986 |
| 41-8 | Cholinesterase Inhibitors Used in Glaucoma | 987 |

| | | |
|-------------------|--|------|
| TABLE 43-1 | Dermatological Dosage Forms | 1013 |
| 43-2 | Popular Emollient Products | 1014 |
| 43-3 | Popular Keratolytic Products | 1015 |
| 43-4 | Topical Local Anesthetics | 1016 |
| 43-5 | Topical Antibiotic Products | 1017 |
| 43-6 | Topical Antifungal Agents | 1018 |
| 43-7 | Topical Debriding Agents | 1021 |
| 43-8 | Topical Burn Preparations | 1023 |

APPENDICES

| | | |
|----------------|--|------|
| TABLE 1 | Nomograms for Children and Adults | 1034 |
| 2A | Biological In Vivo Diagnostic Agents | 1036 |
| 2B | In Vitro Diagnostic Agents | 1038 |
| 3A | Blood Values | 1040 |
| 3B | Hematologic Values | 1041 |
| 3C | Celsius–Fahrenheit Equivalents | 1042 |
| 4A | Specific Antidotes | 1044 |
| 4B | Toxicology: Guidelines | 1045 |
| 5 | Clinically Significant Drug/Food/Herbal Interactions | 1048 |